
|Videos|May 24, 2007
Initial Results of the Ongoing MYSTIC Trial in Stage IV Lung Cancer
Author(s)David R. Gandara, MD
David R. Gandara, MD, professor of Medicine, University of California Davis Comprehensive Cancer Center, discusses the initial results of the ongoing MYSTIC trial, which is exploring the combination of durvalumab (Imfinzi) and tremelimumab versus chemotherapy in stage IV lung cancer.
Advertisement
David R. Gandara, MD, professor of Medicine, University of California Davis Comprehensive Cancer Center, discusses the initial results of the ongoing MYSTIC trial, which is exploring the combination of durvalumab (Imfinzi) and tremelimumab versus chemotherapy in stage IV lung cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Tirzepatide Demonstrates Cardioprotective Effects in T2D With ASCVD
2
Omalizumab-Facilitated OIT Enables Maintenance Dosing in Food Allergy
3
After Sickle Cell Gene Therapy, What Comes Next?
4
Phase 3 Dermatomyositis Trial Sees Brepocitinib Meet Primary Endpoint
5








































































